Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.
Qian Qin(Icahn School of Medicine at Mount Sinai), Che‐Kai Tsao(Mount Sinai Hospital), Elliot Eisenberg(Icahn School of Medicine at Mount Sinai), Danielle Brooks(Icahn School of Medicine at Mount Sinai), Suraj K. Jaladanki(Icahn School of Medicine at Mount Sinai), Philip Garcia(Icahn School of Medicine at Mount Sinai), Parissa Alerasool(New York Medical College), Amanda Leiter(Icahn School of Medicine at Mount Sinai), Matt D. Galsky(Mount Sinai Hospital), Emily J. Gallagher(Icahn School of Medicine at Mount Sinai), Vaibhav G. Patel(Icahn School of Medicine at Mount Sinai), William Oh(Women & Infants Hospital of Rhode Island), Anish B. Parikh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bo Wang(Icahn School of Medicine at Mount Sinai), Emily Carroll(Icahn School of Medicine at Mount Sinai), George Mellgard(Memorial Sloan Kettering Cancer Center)
Cited by 2
Related Papers
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k